Pegylated interferon lambda

Phase 3Small molecule

Bristol-Myers Squibb

Pegylated interferon lambda is one of 97 small molecule programs targeting Hemophilia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

COVID-19Active, not recruiting

Hepatitis CActive, not recruiting

HemophiliaPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Pegylated interferon lambda

Bristol-Myers Squibb

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Aimovig

Amgen

Preclinical

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

SARS-COV-2 VACCINE

Moderna

Preclinical

2 7

Piperacillin/tazobactam

Pfizer

Preclinical

1 8

Orap

Teva

Preclinical

1 9

Calcium

Eli Lilly

Preclinical

—10

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Age2 trials

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01795911·165 enrolled

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01309932·165 enrolled

Hepatitis C2 trials

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01447394

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01616524·880 enrolled

Hemophilia1 trial

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01741545·71 enrolled

COVID-191 trial

Pegylated Interferon Lambda Treatment for COVID-19

Terminated·RRaymond Chung·Phase 2·NCT04343976·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Pegylated interferon lambda. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated interferon lambda compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated interferon lambda. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Pegylated interferon lambda

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Age2 trials

Hepatitis C2 trials

Hemophilia1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News